Guideline Central Blog

• Jaypirca (Eli Lilly)
  • Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor.

• Fabhalta (Novartis)
  • Treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).

• Avzivi (Bio-Thera Solutions) Biosimilar to Avastin
  • Biosimilar to Avastin, multiple indications.

• Casgevy (Vertex / CRISPR)
  • Treatment of sickle cell disease (SCD) in patients 12 years and older.

• Lyfgenia (Bluebird Bio)
  • Treatment of sickle cell disease (SCD) in patients 12 years and older.

• Cresemba (Astellas) Expanded Indication
  • Treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients.

• Iwilfin (US WorldMeds)
  • To treat adult and pediatric patients with high-risk neuroblastoma who have shown at least a partial response to a previous multiagent modality therapy, which includes anti-GD2 immunotherapy.

• Adbry (Leo Pharma)Expanded Indication
  • To include pediatric patients aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

• Alyglo (GC Biopharma)
  • Treatment of adult patients aged 17 years and older with primary humoral immunodeficiency (PI).

• Padcev (Astellas) New Indication 
  • In combination with pembrolizumab (Keytruda) to treat locally advanced or metastatic urothelial cancer.

• Filsuvez (Chiesi) 
  • Treatment of partial thickness wounds in patients 6 months and older with Junctional Epidermolysis Bullosa (JEB) and Dystrophic Epidermolysis Bullosa (DEB).

• Wainua (Ionis Pharmaceuticals)
  • Treatment of Adults with Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.

---

Copyright © 2024 Guideline Central, All rights reserved.